Atossa Therapeutics
ATOS
91 hedge funds and large institutions have $63.3M invested in Atossa Therapeutics in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 21 closing their positions.
65% more call options, than puts
Call options by funds: $8.73M | Put options by funds: $5.29M
0.43% more ownership
Funds ownership: 1.64% → 2.07% (+0.43%)
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
2% less funds holding
Funds holding: 93 → 91 (-2)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
38% less capital invested
Capital invested by funds: $102M → $63.3M (-$38.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$7.93M |
| 2 |
Two Sigma Investments
New York
|
+$5.56M |
| 3 |
Two Sigma Advisers
New York
|
+$3.68M |
| 4 |
Renaissance Technologies
New York
|
+$2.86M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$705K |
| 2 |
HF
HRT Financial
New York
|
-$594K |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$495K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$493K |
| 5 |
Millennium Management
New York
|
-$475K |
ATOS Hedge Fund Activity: Q4 2021 in Review
91 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2021, worth a combined $63.3M — down 38% from $102M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ATOS and 19 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 23 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $7.93M. The largest seller was Mirabella Financial Services, exiting entirely with an estimated $705K sold.
- 91 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2021, down from 93 in Q3 2021.
- Funds reported $63.3M of Atossa Therapeutics stock for Q4 2021, down 38% quarter-over-quarter.
- 19 funds opened new Atossa Therapeutics positions in Q4 2021 and 21 closed out, a net change of -2 holders.
- The largest Atossa Therapeutics buyer in Q4 2021 was D.E. Shaw & Co, an estimated $7.93M added.
- The largest Atossa Therapeutics seller in Q4 2021 was Mirabella Financial Services, an estimated $705K sold.
Based on aggregated 13F filings for Q4 2021.